Skip to main content
. 2018 Oct 17;36(34):3388–3395. doi: 10.1200/JCO.2017.76.4720

Fig 2.

Fig 2.

Outcome of molecularly classified high-grade glioma versus supratentorial embryonal tumor (sET)/pineoblastoma (PBL) tumors. (A) Event-free survival (EFS). Estimated EFS at 5 years for molecularly defined high-grade glioma (HGG) was 5.6% (95% CI, 0% to 13.0%)%, whereas 5-year EFS for supratentorial ET/PBL tumors was 62.8% (95% CI, 43.4% to 82.2%; P < .001). (B) Overall survival (OS). Estimated OS at 5 years for molecularly defined high-grade glioma was 12.0% (95% CI, 0% to 24.7%), whereas 5-year OS for supratentorial ET/PBL tumors was 78.5% (95% CI, 62.2% to 94.8%; P < .001).